Peptides and Proteins
Peptides are short chains of amino acids linked by peptide bonds, whereas proteins are longer and more complex amino acid chains that can adopt functional three-dimensional structures. Both types of compounds are essential for various biological functions, such as catalysing reactions (enzymes), immune defence (antibodies), and cellular signalling. Proteins have a hierarchical structure, including the amino acid sequence, secondary, tertiary, and quaternary structures. Peptides are used in pharmaceutical and cosmetic therapies due to their specific biological properties, such as in the treatment of metabolic diseases or enhancing cellular regeneration. Proteins, on the other hand, have applications in biotechnology, nutrition, and regenerative medicine.
At CymitQuimica, we offer high-purity peptides and proteins for research in biotechnology and therapeutic applications.
Found 3118 products of "Peptides and Proteins"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
3-Mercaptopropionic Acid
CAS:Controlled Product<p>Applications 3-Mercaptopropionic Acid (cas# 107-96-0) is a compound useful in organic synthesis.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br></p>Formula:C3H6O2SColor and Shape:NeatMolecular weight:106.145-9-Leuprolide xTFA Salt
CAS:Controlled Product<p>Applications 5-9-Leuprolide is a metabolite of Leuprolide (L330590), a gonadotropin-releasing hormone (GnRH) analogue acting as an agonist at pituitary GnRH receptors.<br>References Handelsman, David J., et al.: J. of Steroid Biochem. and Mol. Bio., 141, 113-120 (2014);Okada, Hiroaki, et al.: Pharma. Res., 8(6), 787-91 (1991)<br></p>Formula:C34H57N9O6·x(C2HF3O2)Color and Shape:NeatMolecular weight:687.87+ x(114.02)Carfilzomib (2S,4R)-Diol
Controlled Product<p>Applications Carfilzomib (2S,4R)-Diol is a derivative of Carflizomib (C183460), a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.<br>References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);<br></p>Formula:C40H59N5O8Color and Shape:NeatMolecular weight:737.933,3’,5-Triiodo-L-thyronine
CAS:Controlled ProductFormula:C15H12I3NO4Color and Shape:White To Off-WhiteMolecular weight:650.97Cyclosporin H
CAS:<p>Applications Cyclosporin is an immunosuppressant that has revolutionized organ transplantation through its use in the prevention of graft rejection.A group of nonpolar cyclic oligopeptides with immunosupppressant activity.<br>References van Wartburg, A., et al.: Prog. Med. Chem., 25, 1 (1988), Jorgensen, K.A., et al.: Scand. J. Imunol., 57, 93 (2003), Vollenbroeker, et al.: Transplant. Proc., 37, 1741 (2005),<br></p>Formula:C62H111N11O12Color and Shape:NeatMolecular weight:1202.61Boceprevir (>90%)
CAS:Controlled ProductFormula:C27H45N5O5Purity:>90%Color and Shape:NeatMolecular weight:519.68N-des-succinyl-Sacubitril hydrochloride
CAS:Controlled Product<p>Applications (2R,4S)-4-Amino-5-(biphenyl-4-yl)-2-methylpentanoic Acid Ethyl Ester Hydrochloride is used as a reagent in the synthesis of LCZ696, an angiotensin II receptor and neprilysin receptor dual inhibitor. (2R,4S)-4-Amino-5-(biphenyl-4-yl)-2-methylpentanoic Acid Ethyl Ester Hydrochloride is also used as a reagent in the preparation of novel NEP inhibitor prodrugs for the treatment of hypertension and cardiovascular diseases.<br>References Liu, M., et al.: Faming Zhuanli Shenqing. CN 105168205 A 20151223. Dec 23, 2015; Wang, Z.: PCT Int. Appl. WO 2015154673 A1 20151015. Oct 15, 2015<br></p>Formula:C20H25NO2·HClColor and Shape:NeatMolecular weight:384.346-Perdeoxy-6-perchloro-γ-cyclodextrin, >90%
CAS:Formula:C48H72Cl8O32Purity:>90%Color and Shape:NeatMolecular weight:1444.69Carfilzomib
CAS:Controlled Product<p>Applications Carfilzomib is a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.<br>References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);<br></p>Formula:C40H57N5O7Color and Shape:White To Off-WhiteMolecular weight:719.91D-Ser-(12)-Semaglutide
<p>D-Ser(12)-Semaglutide is a semaglutide impurity. The amino acid at position 12 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molD-Thr(5)-Semaglutide
<p>D-Thr(5)-Semaglutide is a semaglutide impurity. The amino acid at position 5 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molDes-Glu(3)-Semaglutide
<p>Des-Glu(3)-semaglutide is a semaglutide-related impurity. This des-amino acid form has got the glutamic acid or glutamate (Glu) amino acid from position 3 removed from the peptide chain. Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist used for managing type 2 diabetes and obesity.</p>Formula:C182H284N44O56Molecular weight:3,984.53 g/molD-Asp(9)-Semaglutide
<p>D-Asp(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the D-form of the amino acid D-aspartic acid (D-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/mol3,3',5,5'-Tetraiodothyroformic acid
CAS:<p>Cymit Quimicaetic beta-D-glucosiduronic acid</p>Formula:C13H6I4O4Purity:Min. 95 Area-%Color and Shape:Off-White PowderMolecular weight:733.8 g/molD-Ser(8)-Semaglutide
<p>D-Ser(8)-Semaglutide is a semaglutide impurity. The amino acid at position 8 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molBortezomib intermediate I
CAS:<p>Bortezomib intermediate I is a metabolite of bortezomib, which is a research and development drug product. Bortezomib intermediate I is an impurity standard for bortezomib. Bortezomib intermediate I can be synthesized from the corresponding compound. It is an analytical standard used in pharmacopoeia and can be used as an API impurity or synthetic material in drug development. Bortezomib intermediate I has a high purity, natural origin, and a niche application. CAS No. 1248339-44-7</p>Formula:C25H36BN5O4Purity:Min. 95%Color and Shape:White PowderMolecular weight:481.4 g/molD-His(1)-Semaglutide
<p>D-His(1)-Semaglutide is a semaglutide impurity. The amino acid at position 1 has been replaced by the D-form of the amino acid D-histidine (D-His). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molSemaglutide Impurity 60 (D-Arg 30)
<p>D-Arg(30)-Semaglutide is a semaglutide impurity. The amino acid at position 30 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/mol(S,E)-N-(1-(3-Methylbut-1-enylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide
CAS:<p>R-N-(1-(3-methylbut-1-enyl)-1-oxo-3-phenylpropan-2-yl) pyrazine-2-carboxamide is a drug product that is used for the treatment of bacterial infections. The compound is an impurity in the synthesis of other compounds and is also used as an analytical standard. It is synthesized from commercially available starting materials and through custom synthesis. R-N-(1-(3-methylbut-1-enyl)-1--oxo--3--phenylpropan--2--yl)pyrazine--2--carboxamide has been shown to be metabolized by CYP450 enzymes, which are responsible for the metabolism of many drugs. R-(1-(3Methylbut 1Enylamino)-1Oxo 3Phenylpropan 2Yl)Pyrazine 2Carboxamide has not been evaluated as a drug product and therefore does not</p>Formula:C19H22N4O2Purity:Min. 95%Molecular weight:338.4 g/molD-Phe(6)-Semaglutide
<p>D-Phe(6)-Semaglutide is a semaglutide impurity. The amino acid at position 6 has been replaced by the D-form of the amino acid D-phenylalanine (D-Phe). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molSemaglutide Impurity 51 (D-Thr 7)
<p>D-Thr(7)-Semaglutide is a semaglutide impurity. The amino acid at position 7 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molD-Ala-(19)-Semaglutide
<p>D-Ala(19)-Semaglutide is a semaglutide impurity. The amino acid at position 19 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molSemaglutide Impurity 29 (β-Asp-9)
<p>Beta-Asp-(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the beta-aspartic acid (also known as isoaspartic, isoAsp, β-Asp or beta-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molLinear Semaglutide
<p>Linear semaglutide, or simply L-Sema, is the semaglutide compound without the lipid side chain modification. It is essentially a linear version of the peptide.</p>Formula:C152H230N42O47Molecular weight:3,397.76 g/molLisinopril EP Impurity E
CAS:<p>Lisinopril EP Impurity E is an impurity of lisinopril, which is a prescription drug used to treat high blood pressure. This impurity was found in a preparative high performance liquid chromatography (HPLC) and mass spectroscopy analysis of the drug. The molecular weight of Lisinopril EP Impurity E was determined to be 317.2 amu, which corresponds to the molecular formula C7H13NO2. The FT-IR spectrum showed that this impurity has an ammonium group at 1859 cm-1 and butanoic acid at 1647 cm-1.</p>Formula:C21H31N3O5Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:405.49 g/molSemaglutide Impurity 56 (D-Glu 21)
<p>D-Glu(21)-Semaglutide is a semaglutide impurity. The amino acid at position 21 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molD-Ser(11)-Semaglutide
<p>D-Ser(11)-Semaglutide is a semaglutide impurity. The amino acid at position 11 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molSemaglutide Impurity 59
<p>D-Arg(28)-Semaglutide is a semaglutide impurity. The amino acid at position 28 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molSemaglutide Impurity 54 (D-Ala 18)
<p>D-Ala(18)-Semaglutide is a semaglutide impurity. The amino acid at position 18 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/mol(R)-3-Methyl-1-(pyrazine- 2-carboxamido)butylboronic acid
<p>The compound is a drug product, analytical, and research material. The molecule has been synthesized and purified by the company's chemists. It is not an API impurity but an impurity standard for HPLC. This compound is a synthetic chemical that does not occur naturally in any living organism. It has been developed for use in drug development and research. The compound was custom synthesized by the company's chemists to meet customer demand for high purity standards of this compound. It is used as a pharmacopoeia standard for HPLC analysis and drug development.</p>Purity:Min. 95%D-Val(10)-Semaglutide
<p>D-Val(10)-Semaglutide is a semaglutide impurity. The amino acid at position 10 has been replaced by the D-form of the amino acid D-valine (D-Val). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molSemaglutide Impurity 101 (D-Glu 3)
<p>D-Glu(3)-Semaglutide is a semaglutide impurity. The amino acid at position 3 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molDes-His(1)-Semaglutide
<p>Des-His(1)-semaglutide is a semaglutide-related impurity. This des-amino acid form has the histidine (His) amino acid from position 1 removed from the peptide chain. Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist used for managing type 2 diabetes and obesity.</p>Formula:C181H284N42O58Molecular weight:3,976.5 g/molD-Ala(24)-Semaglutide
<p>D-Ala(24)-Semaglutide is a semaglutide impurity. The amino acid at position 24 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Formula:C187H291N45O59Molecular weight:4,113.64 g/molLisinopril
CAS:<p>Lisinopril, an ACE inhibitor, treats hypertension, heart failure, heart attacks, and prevents diabetes-related eye and kidney issues.</p>Formula:C21H31N3O5Purity:97.59% - 99.34%Color and Shape:SolidMolecular weight:405.49(1S,2S)-Bortezomib
CAS:Controlled Product<p>Impurity Bortezomib USP Impurity G<br>Stability Hygroscopic<br>Applications (1S,2S)-Bortezomib is an isomer of Bortezomib (B675700), proteasome inhibitor. (1S,2S)-Bortezomib has been seen to inhibit serine proteases shown to lower cellular Aβ concentrations, associated with Alzheimer’s or hypertension.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hardy, J. et al.: Science, 297, 353 (2002); Paris, D. et al.: Mol. Med. 17, 149 (2011);<br></p>Formula:C19H25BN4O4Color and Shape:NeatMolecular weight:384.24(S)-(-)-α-Methylbenzylamine
CAS:Controlled Product<p>Applications (S)-(-)-α-Methylbenzylamine (cas# 2627-86-3) is a compound useful in organic synthesis.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br></p>Formula:C8H11NColor and Shape:NeatMolecular weight:121.18(2,6-Dimethylphenoxy)acetic Acid
CAS:Controlled ProductFormula:C10H12O3Color and Shape:NeatMolecular weight:180.204-(Phenylamino)-1-benzyl-4-piperidinecarboxamide
CAS:Controlled Product<p>Applications Used as modulators of muscarinic receptors for treatment of CNS disorders.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Coghlan, M., et al.: J. Med. Chem., 44, 1627 (2001), Ashcroft, F., et al.: J. Clin. Invest., 115, 2047 (2005), Bryan, J., et al.: Curr. Pharm. Des., 11, 2699 (2005),<br></p>Formula:C19H23N3OColor and Shape:NeatMolecular weight:309.41Semaglutide impurity
CAS:<p>Lipid chain (stearic bi-acid) plus γ-glutamic acid or glutamate (γ-Glu) amino acid.</p>Formula:C35H63N3O13Molecular weight:733.89 g/molAlamethicin
CAS:<p>Alamethicin is isolated from Trichoderma viride. It is a channel-forming peptide antibiotic and induces voltage-gated conductance in model and cell membranes.</p>Formula:C92H150N22O25Purity:98%Color and Shape:SolidMolecular weight:1964.31CP5V
CAS:<p>CP5V, a PROTAC, degrades Cdc20, halts mitosis, and inhibits cancer growth by targeting it for VHL-mediated ubiquitination and proteasome destruction.</p>Formula:C46H66Cl3N9O12SPurity:98%Color and Shape:SolidMolecular weight:1075.49(S)-4-Oxo-homophenylalanine Hydrochloride
CAS:Controlled Product<p>Stability Hygroscopic<br>Applications (S)-4-Oxo-homophenylalanine Hydrochloride is a derivative of L-Homophenylalanine (H600500); an antitumor agent.<br>References Brunner, Henri., et al.: Eur. J. Med. Chem., 25, 35 (1990)<br></p>Formula:C10H12ClNO3Color and Shape:NeatMolecular weight:229.66t-Butyl 4-Bromobutanoate
CAS:Controlled Product<p>Applications t-Butyl 4-bromobutanoate is a useful research chemical for organic synthesis and other chemical and pharmaceutical processes.<br>References Brudeli, B., et al.: Bioorg. Med. Chem., 18, 8600 (2010); Colak, S., et al.: Macromolecules, 41, 8436 (2008)<br></p>Formula:C8H15BrO2Color and Shape:NeatMolecular weight:223.11Cyclosporin AM 4N
CAS:Controlled ProductFormula:C61H109N11O12Color and Shape:NeatMolecular weight:1188.58Dodecyl Polyoxyethylene (23) Aldehyde
CAS:Controlled Product<p>Applications Polyoxyethylene (23) Lauric Acid is an intermediate in the synthesis of Bril L-23 Proline (LIFETC1), a polyethylene glycol derivative of Proline (P755995), an amino acid and precursor (with vitamin C) for collagen, the building block of the structure of tendons, ligaments, arteries, veins and muscles.<br>References Bondarenko, L.B., et al.: Int. J. Peptides., 2, 1687 (2012); Rimer, T., et al.: Biomacromolecules, 13, 2110 (2012);<br></p>Formula:C14H28O2(C2H4O)nColor and Shape:NeatTrofinetide (>90%)
CAS:Controlled Product<p>Applications Trofinetide is a synthetic analogue of the endogenous N-terminus tripeptide, Glycine-Proline-Glutamate (GPE), that has shown to be neuroprotective in animal models of brain injury.<br>References Wei, H.H. et al.: J Neuroinflammation. 2009 Aug 5;6:19.<br></p>Formula:C13H21N3O6Purity:>90%Color and Shape:NeatMolecular weight:315.32Linear Daptomycin Hydrochloride Salt
CAS:<p>Applications Linear Daptomycin Hydrochloride Salt is the hydrochloride salt of L466470, which is the open-conformation of Daptomycin (D193350), cyclic lipopeptide antibiotic derived from a fermentation product of Streptomyces roseosporus; disrupts plasma membrane function in gram-positive bacteria. Antibacterial. Daptomycin Impurity<br>References Allen, N.E., et al.: Antimicrob. Agents Chemother., 31, 1093 (1987), Tully, F.P., et al.: Expert Opin. Invest. Drugs, 8, 1223 (1999),<br></p>Formula:C72H103N17O27·x(ClH)Purity:~80%Color and Shape:NeatMolecular weight:1638.69 + x(36.46)N-(1-Carboxy-3-phenylpropyl)-S-lisinopril (Mixture of diastereomers)
CAS:Controlled Product<p>Applications N-(1-Carboxy-3-phenylpropyl)-S-lisinopril (Mixture of diastereomers) is an impurity of lisinopril (L468985), an orally active angiotensin-converting enzyme (ACE) inhibitor.<br>References Shinde, V., et. al.: J. Pharm. Biomed. Anal., 43, 381 (2007); Goa, K.L., et al.: Drugs, 52, 564 (1996), Chaturvedi, N., et al.: Lancet, 351, 28 (1998)<br></p>Formula:C31H41N3O7Color and Shape:NeatMolecular weight:567.679-(2,5-d|-Dioxo-L-3-amino-1-pyrrolidineacetic acid)-10-deglycine Daptomycin
CAS:Controlled Product<p>Applications 9-(2,5-d|Dioxo-L-3-amino-1-pyrrolidineacetic acid)-10-deglycine Daptomycin is a stereoisomer of Daptomycin (D193350), cyclic lipopeptide antibiotic derived from a fermentation product of Streptomyces roseosporus; disrupts plasma membrane function in gram-positive bacteria. Antibacterial.<br>References Allen, N.E., et al.: Antimicrob. Agents Chemother., 31, 1093 (1987), Tully, F.P., et al.: Expert Opin. Invest. Drugs, 8, 1223 (1999),<br></p>Formula:C72H99N17O25Color and Shape:NeatMolecular weight:1602.66
